These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 27564251)
1. LpMab-19 Recognizes Sialylated O-Glycan on Thr76 of Human Podoplanin. Ogasawara S; Kaneko MK; Kato Y Monoclon Antib Immunodiagn Immunother; 2016 Oct; 35(5):245-253. PubMed ID: 27564251 [TBL] [Abstract][Full Text] [Related]
2. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Kaneko MK; Nakamura T; Honma R; Ogasawara S; Fujii Y; Abe S; Takagi M; Harada H; Suzuki H; Nishioka Y; Kato Y Cancer Med; 2017 Feb; 6(2):382-396. PubMed ID: 28101903 [TBL] [Abstract][Full Text] [Related]
3. Establishment of Mouse Monoclonal Antibody LpMab-13 Against Human Podoplanin. Ogasawara S; Kaneko MK; Honma R; Oki H; Fujii Y; Takagi M; Suzuki H; Kato Y Monoclon Antib Immunodiagn Immunother; 2016 Oct; 35(5):254-258. PubMed ID: 27148766 [TBL] [Abstract][Full Text] [Related]
4. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin. Kato Y; Ogasawara S; Oki H; Goichberg P; Honma R; Fujii Y; Kaneko MK PLoS One; 2016; 11(3):e0152912. PubMed ID: 27031228 [TBL] [Abstract][Full Text] [Related]
5. Establishment of Mouse Monoclonal Antibody LpMab-13 Against Human Podoplanin. Ogasawara S; Kaneko MK; Honma R; Oki H; Fujii Y; Takagi M; Suzuki H; Kato Y Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):155-62. PubMed ID: 27328060 [TBL] [Abstract][Full Text] [Related]
6. LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin. Yamada S; Ogasawara S; Kaneko MK; Kato Y Monoclon Antib Immunodiagn Immunother; 2017 Apr; 36(2):72-76. PubMed ID: 28387591 [TBL] [Abstract][Full Text] [Related]
7. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity. Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal Antibody LpMab-9 Recognizes O-glycosylated N-Terminus of Human Podoplanin. Kaneko MK; Oki H; Hozumi Y; Liu X; Ogasawara S; Takagi M; Goto K; Kato Y Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):310-7. PubMed ID: 26492618 [TBL] [Abstract][Full Text] [Related]
9. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352 [TBL] [Abstract][Full Text] [Related]
10. Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin. Kato Y; Ogasawara S; Oki H; Honma R; Takagi M; Fujii Y; Nakamura T; Saidoh N; Kanno H; Umetsu M; Kamata S; Kubo H; Yamada M; Sawa Y; Morita K; Harada H; Suzuki H; Kaneko MK Monoclon Antib Immunodiagn Immunother; 2016 Apr; 35(2):109-16. PubMed ID: 26937552 [TBL] [Abstract][Full Text] [Related]
11. Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin. Oki H; Ogasawara S; Kaneko MK; Takagi M; Yamauchi M; Kato Y Monoclon Antib Immunodiagn Immunother; 2015 Feb; 34(1):44-50. PubMed ID: 25723283 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312 [TBL] [Abstract][Full Text] [Related]